Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Lincomycin Hydrocloride
Lincomycin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Lincomycin - Active Comparative - Hard Gelatin Capsule | ACTIVE_COMPARATOR | - |
| Lincomycin - Study Drug - Hard Gelatin Capsule | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Lincomycin | DRUG | Single Dose Hard Gelatin Capsule - oral - 500 mg |
Inclusion Criteria: * Men. * Women who are not pregnant nor nursing. * Age between 18 and 50 years-old. * Body mass index ≥ 19 and ≤ 28,5. * Good health conditions or with no significant diseases, under judgement of the legally qualified professional, according to the rules defined in the Protocol,...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Lincomycin is a small molecule antibiotic used for the treatment of bacterial infections. It is being developed by Pfizer, Inc. for this indication. The drug is currently in Phase 1 clinical development, meaning it is investigational and has not yet been approved for commercial use.
Lincomycin is being developed by Pfizer, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is in Phase 1 clinical development for the treatment of bacterial infections.
Lincomycin is in Phase 1 clinical development. It is an investigational drug for the treatment of bacterial infections and has not yet been approved by regulatory authorities. One Phase 1 clinical trial has been completed to evaluate the drug.
Lincomycin has one completed Phase 1 clinical trial registered under NCT01058824. The study was a relative bioavailability study of two lincomycin hydrochloride hard gelatinous capsules, conducted in Brazil with 36 participants, including healthy volunteers aged 18 years and older.
Lincomycin is the active drug, and it is often formulated as lincomycin hydrochloride for oral administration. The clinical trial NCT01058824 evaluated lincomycin hydrochloride hard gelatinous capsules, indicating that the hydrochloride salt form is used in the drug product being studied.